8-K: Arcus Biosciences Halts Key Cancer Trials

Arcus Biosciences announced the discontinuation of its Phase 3 STAR-221 and Phase 2 EDGE-Gastric studies for advanced gastric and esophageal cancers due to futility.

Summary

• Arcus Biosciences discontinued its Phase 3 STAR-221 study and Phase 2 EDGE-Gastric studies.
• The studies evaluated domvanalimab plus zimberelimab and chemotherapy as a first-line treatment for advanced gastric and esophageal cancers.
• The decision was based on a recommendation from the Independent Data Monitoring Committee following an event-driven, pre-specified interim analysis of overall survival (OS).
• At the interim analysis, the domvanalimab-based combination did not improve OS relative to nivolumab plus chemotherapy.
• The safety profile for the domvanalimab-based combination was similar to nivolumab plus chemotherapy, with no new safety findings identified.
• The company expects to be able to fund its planned operations until at least the second half of 2028, based on existing cash, cash equivalents, and marketable securities.
• Future R&D investment and resources will focus on casdatifan, a potential best-in-class HIF-2a inhibitor, and emerging small molecule inflammation and autoimmune programs.
• An MRGPRX2 inhibitor, part of the new focus, is expected to enter the clinic in 2026.

Sentiment

Score: 3

Explanation: The discontinuation of a Phase 3 study due to futility is a major negative event for a biotechnology company, indicating a failure in a key clinical program. However, the company's strong cash runway extending to the second half of 2028 and the strategic pivot to other pipeline assets (casdatifan, MRGPRX2 inhibitor) provide some mitigation, preventing a lower score.

Positives

• Company maintains a strong cash runway, expecting to fund operations until at least the second half of 2028.
• Strategic pivot to focus R&D investment on other promising programs, including casdatifan and emerging small molecule inflammation and autoimmune programs.
• An MRGPRX2 inhibitor is expected to enter the clinic in 2026, indicating pipeline progression in other areas.

Negatives

• Discontinuation of the Phase 3 STAR-221 study due to futility.
• The domvanalimab-based combination failed to improve overall survival (OS) in advanced gastric and esophageal cancers.
• Discontinuation of the Phase 2 EDGE-Gastric study.
• Represents a significant setback for the anti-TIGIT antibody domvanalimab program in this specific indication.

Risks

• Changes in the company's strategy and operating plans.
• Preliminary and interim data are not guarantees that future data will be similar.
• Unexpected emergence of adverse events or other undesirable side effects in investigational products, including casdatifan.
• Adverse data from toxicology studies affecting the company's ability to advance development candidates from its immunology and inflammation programs.
• Uncertainties in timelines associated with the conduct of clinical studies and with respect to the regulatory approval process.
• Changes in the competitive landscape for the company's programs.
• Inherent uncertainty associated with pharmaceutical product development and clinical trials.

Future Outlook

The company expects to fund its planned operations until at least the second half of 2028. R&D investment will shift focus to casdatifan, a potential best-in-class HIF-2a inhibitor, and emerging small molecule inflammation and autoimmune programs, with an MRGPRX2 inhibitor anticipated to enter the clinic in 2026.

Management Comments

• The decision is based on the recommendation from the Independent Data Monitoring Committee following its review of data from an event-driven, pre-specified interim analysis of overall survival (OS).
• At the interim analysis, the domvanalimab-based combination did not improve OS relative to nivolumab plus chemotherapy.
• The safety profile for the domvanalimab-based combination was similar to that of nivolumab plus chemotherapy, and there were no new safety findings identified.
• The STAR-221 and the Phase 2 EDGE-Gastric studies will be discontinued, and the Company and Gilead Sciences, Inc. are communicating with investigators to determine appropriate next steps for patients in the study, in addition to conducting a detailed analysis to better understand these results.
• Based on existing cash, cash equivalents and marketable securities, the Company expects to be able to fund its planned operations until at least the second half of 2028.
• Moving forward, the Company's R&D investment and resources will focus on casdatifan, a potential best-in-class HIF-2a inhibitor, and its emerging small molecule inflammation and autoimmune programs, including an MRGPRX2 inhibitor that is expected to enter the clinic in 2026.

Industry Context

This announcement represents a significant setback for the TIGIT inhibitor class in advanced gastric and esophageal cancers, particularly for the combination of domvanalimab and zimberelimab. The TIGIT pathway has been a highly anticipated target in oncology, but several trials have faced challenges. This outcome may lead to increased scrutiny and re-evaluation of TIGIT-based strategies by other companies in the competitive oncology landscape, potentially shifting focus to other mechanisms or patient populations where TIGIT inhibitors might show more promise.

Comparison to Industry Standards

• The failure of the domvanalimab-based combination to improve overall survival against nivolumab plus chemotherapy in advanced gastric and esophageal cancers is a negative outcome, especially given the high expectations for TIGIT inhibitors in oncology.
• This result is comparable to other TIGIT failures, such as Roche's tiragolumab in lung cancer (SKYSCRAPER-01), which also failed to meet its primary endpoint of overall survival, raising questions about the broad applicability and efficacy of the TIGIT class as a whole.
• Nivolumab (Opdivo, Bristol Myers Squibb) is an established PD-1 inhibitor, and its performance as a comparator sets a high bar, indicating that the domvanalimab combination did not offer a superior clinical benefit in this specific indication.

Stakeholder Impact

• Shareholders: Likely negative impact due to the failure of a late-stage clinical trial, potentially leading to a decrease in share price. The strategic pivot and cash runway offer some long-term hope but immediate sentiment will be negative.
• Patients: Patients enrolled in the STAR-221 and EDGE-Gastric studies will have their treatment regimens re-evaluated, and alternative options will be discussed with investigators.
• Employees: R&D focus shift may lead to reallocation of resources and personnel, though no direct impact on employment is stated.
• Gilead Sciences, Inc.: As a partner, Gilead will also be impacted by the discontinuation of the studies and will be involved in the next steps for patients and data analysis.

Next Steps

• Company and Gilead Sciences, Inc. will communicate with investigators to determine appropriate next steps for patients in the discontinued studies.
• Conduct a detailed analysis to better understand the results of the STAR-221 and EDGE-Gastric studies.
• Focus R&D investment and resources on casdatifan (HIF-2a inhibitor).
• Focus R&D investment and resources on emerging small molecule inflammation and autoimmune programs.
• Advance an MRGPRX2 inhibitor into the clinic in 2026.

Key Dates

Recommendation

The discontinuation of a Phase 3 clinical trial due to futility for a key oncology asset (domvanalimab) is a significant negative catalyst for a biotechnology company. While the company has a cash runway until H2 2028 and is pivoting to other programs, the failure of a late-stage asset typically leads to a substantial re-rating of the stock downwards. Investors should consider selling to mitigate further downside risk, as the market will likely discount the value of the TIGIT program and re-evaluate the entire pipeline's risk profile. The future programs are still early-stage, carrying high development risk.

Keywords

Arcus Biosciences, RCUS, STAR-221, EDGE-Gastric, domvanalimab, zimberelimab, nivolumab, TIGIT, PD-1, gastric cancer, esophageal cancer, clinical trial, futility, oncology, biotechnology, casdatifan, HIF-2a inhibitor, MRGPRX2 inhibitor, immunology, inflammation, autoimmune